patritumab
Daiichi Sankyo,Amgen
['mbc', 'her3-dxd', 'bcsm']
don't miss the chance to hear discuss the recent phase 2 results examining the efficacy of her3-dxd across #mbc subsets and defining potential target patient population. #meded #bcsm #asco23 
COR2ED bringing you Independent Medical Education developed by BREAST CANCER CONNECT, international experts in Breast Cancer.